News

(Update with New Jersey Attorney General Jennifer Davenport's statement on the lawsuit in the penult

Amazon.com (AMZN) stock is in focus after a consumer lawsuit filed on July 31, 2026, alleged the retailer sold Orgain protein powder containing harmful levels of heavy metals and misrepresented the products’ safety and quality attributes. See our latest analysis for Amazon.com. After the latest lawsuit headlines, Amazon.com’s recent share price moves still reflect strong momentum, with a 7 day share price return of 23.03% and a 1 year total shareholder return of 32.87%, which points to...

A European court rejected Broadcom's attempt to block regulators from demanding U.S.-based VMware legal documents.

California’s governor warns that an antitrust lawsuit threatening the media mega-merger could severely damage local entertainment industry jobs.

The California governor has told people involved in the suit that blocking the $81 billion deal could harm Hollywood jobs.

LONDON, July 27 (Reuters) - Elon Musk's Tesla on Monday won its bid to revive a London lawsuit brought against U.S. technology firm InterDigital and a patent licensing platform, seeking a patent

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.

Court strips shareholder case of class-action status

Investing.com -- Apple Inc. and the US Justice Department are in early discussions to settle a 2024 antitrust lawsuit, Bloomberg reported Friday.

Apple ‌and ‌the U.S. Department ​of Justice are in ‌early ⁠discussions about settling ⁠a 2024 ​lawsuit ​that ​alleges the ‌iPhone maker violated antitrust laws, ‌Bloomberg ​News ​reported ​on ‌Friday. Reuters could not ​immediately ​verify the ​report. (Reporting ‌by Jaspreet ​Singh in ​Bengaluru)

(Bloomberg) -- Apple Inc. and the US Justice Department are in early discussions about settling a 2024 lawsuit that alleges the iPhone maker violated antitrust laws. Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesChip Stocks Poised for Bear Market in AI Unwind: Markets WrapGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsChina’s Moonshot Unveils AI Model That Narrows Gap With US FirmsThailand Scraps Plan to End Visa-Free Entry for Indian Tour

The daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

European cloud and infrastructure groups have challenged Broadcom over recent VMware licensing changes following the acquisition. Trade association CISPE and others have asked EU antitrust regulators to review and suspend certain Broadcom practices tied to VMware contracts. The European Commission has opened an antitrust review that centers on access, pricing, and conditions for VMware software in the region. Broadcom (NasdaqGS:AVGO) is coming under closer regulatory scrutiny in Europe at a...

Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for […]

Just one day after glowing reviews, a surprise revenue warning sent the stock into a tailspin and brought lawyers to the door.

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Alphabet unit Google on Wednesday urged Europe's top court to dismiss EU antitrust regulators' appeal ‌against a lower court ruling that scrapped a €1.49 billion ($1.7 billion) fine, saying ‌the regulators' arguments were flawed. The dispute reached the Court of Justice of the European Union ​after regulators appealed a 2024 General Court ruling that annulled the fine imposed on Google in 2019. The lower court cited errors in the European Commission's assessment of the case.

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.

Carr expressed his views on the Paramount-Warner Bros. Discovery merger, antitrust concerns and Disney’s DEI-related investigations.

Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This approval opens an additional use for this oncology drug. See our latest analysis for Pfizer. Despite the positive IBRANCE news and a long dividend track record, Pfizer’s recent share price performance has been weak. The stock is down over the past month and quarter, while the 1-year total...

PARIS, July 8 (Reuters) - France's competition authority on Wednesday ordered Meta Platforms to resume talks with French media groups over payments for publishing content, after the publishers

Ford ranked No. 1 among mass-market brands in J.D. Power's initial quality study.

European Court of Justice upholds a €4.1b antitrust fine against Alphabet on its Android practices. Ruling is final and concludes a multi year legal dispute over Android market dominance in Europe. Decision increases regulatory pressure on Alphabet's core search and mobile ecosystems globally. For investors tracking Alphabet, ticker NasdaqGS:GOOGL, this ruling directly touches the foundations of its Android, search, and app distribution businesses. Alphabet runs one of the most widely used...

The judgment concludes a legal dispute that began after the European Commission fined Google in 2018 for abusing market dominance.

Alphabet Inc (NASDAQ:GOOG) shares traded about 1% lower on Thursday after the European Court of Justice (ECJ) upheld a €4.1 billion ($4.67 billion) antitrust fine against Google over its Android mobile operating system. The ruling marks the end of Google's legal challenge against the European...

EU court backs regulators in long-running case.

Europe's top court upheld findings that Google abused Android's market dominance.

On this episode of Stock Movers: - SoftBank (SFTBY) shares are responding to news that it is starting a new U.S. venture to rent out the computing power needed to build and run artificial-intelligence models, aiming to capitalize on strong American demand for AI computing resources. - Shares of Alphabet/Google (GOOG) are responding to the company losing its long-running fight against a 4.1 billion ($4.7 billion) European Union antitrust fine after the bloc's top judges said regulators were right to punish the US giant for abusing Android's market power.

Alphabet's Google on Thursday lost its fight against a record fine imposed by ‌EU antitrust regulators eight years ago for using its Android mobile operating ‌system to block rivals, a court ruling likely to boost Europe's crackdown on Big Tech. The European ​Commission had originally handed out a €4.34 billion fine to Google in 2018 for its agreements which forced phone manufacturers to pre-install Google Search, the Chrome browser and the Google Play app store on their Android devices and prevented them from using rival ‌Android systems. Google then appealed ⁠to the Luxembourg-based Court of Justice of the European Union, Europe's highest.